Request Copyright Permission

Asthma Rescue with Carbonated Perflubron: A Novel Biophysical Approach

Dennis JH.

Respiratory Drug Delivery 2016. Volume 1, 2016: 23-36.

Abstract:

Asthma presents the Western world’s most common respiratory disease with considerable morbidity and mortality. Around 25% of patients presenting to the emergency room or EMS do not respond well to conventional β2-agonist and steroid treatment regimes and are admitted to the hospital, incurring significant costs to health care systems. We are developing a new class of bronchodilator, S1226, which has a novel mechanism of action to rapidly bronchodilate constricted airways. A Phase I and ongoing Phase II clinical trials demonstrate safety in both healthy and asthmatic adults. Reporting of efficacy from our S1226 Phase II trial is imminent. If S1226 proves as efficacious in human asthma as in animal models of asthma, we expect S1226 may fill a significant unmet need in the treatment of acute asthma.